Relapsed or Refractory Mantle Cell Lymphoma (MCL) Clinical Trials in Beijing, Beijing Municipality
2 recruitingBeijing, Beijing Municipality, China
Showing 1–2 of 2 trials
Recruiting
Phase 2
A Study to Evaluate the Efficacy and Safety of ICP-248 in Subjects With Relapsed or Refractory Mantle Cell Lymphoma (APEX-06)
Relapsed or Refractory Mantle Cell Lymphoma (MCL)
Beijing InnoCare Pharma Tech Co., Ltd.75 enrolled29 locationsNCT07082686
Recruiting
Phase 2
Glofitamab Combined With Lenalidomide in High Risk Patients With Relapsed or Refractory Mantle Cell Lymphoma
MCLRelapsed or Refractory Mantle Cell Lymphoma (MCL)
Peking University Third Hospital43 enrolled1 locationNCT07460362